Johnson & Johnson (J&J) is further curtailing its participation in the controversial 30-year-old 340B Drug Discount Program, which was designed to serve low-income patient populations in the U.S.
Source: Drug Industry Daily
Johnson & Johnson (J&J) is further curtailing its participation in the controversial 30-year-old 340B Drug Discount Program, which was designed to serve low-income patient populations in the U.S.
Source: Drug Industry Daily